Actively Recruiting
Olverembatinib for FGFR1-rearranged Neoplasms
Led by The First Affiliated Hospital of Soochow University · Updated on 2022-08-30
20
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
FGFR1-rearranged myeloid/lymphoid neoplasms are a rare hematologic malignancy with very poor outcome despite intensive chemotherapy. The only curative option is thought to be allogeneic hematopoietic stem cell transplantation (HSCT) in remission. This phase II study is aimed to evaluate the efficacy of Olverembatinib, consolidated with HSCT in the treatment of FGFR1-rearranged myeloid/lymphoid neoplasm.
CONDITIONS
Official Title
Olverembatinib for FGFR1-rearranged Neoplasms
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with newly diagnosed, progressed or relapsed myeloid/lymphoid neoplasms with FGFR1 rearrangement according to WHO-2016 diagnostic criteria
- ECOG score: 0-3 points for myeloproliferative neoplasms, 0-2 points for acute leukemia patients
- Expected survival period of at least 12 weeks
- Willingness and ability to comply with study procedures and follow-up examinations
You will not qualify if you...
- Patients who have received allogeneic hematopoietic stem cell transplantation or ponatinib
- Infection with HIV, chronic hepatitis B (HBsAg positive), or hepatitis C (anti-HCV positive)
- Pregnant, planning to become pregnant, or breastfeeding
- Unable to complete all study visits or procedures, including follow-up
- Any condition or illness that could compromise safety or interfere with drug safety evaluation according to investigator's opinion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China, 215000
Actively Recruiting
Research Team
S
Suning Chen
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here